Dr Nerea Alonso graduated in Biochemistry from the University of Salamanca, Spain in 2003 and then she received her PhD in Cancer Biology and Clinical Studies at the same University. Her PhD research focused on the molecular analysis of patients with Gorlin syndrome, a rare disease involving developmental alterations and basal cell carcinomas. In 2008 she moved to Edinburgh, UK, joining the Rheumatology and Bone Disease Unit as a postdoctoral research fellow. She has been working on the characterisation of a model for Paget’s disease of bone and she has been active part of an international consortium to study osteoporosis (GEFOS), leading a collaborative effort to identify genetic variants predisposing to clinical vertebral fractures in postmenopausal females. Dr Alonso is also interested in pharmacogenomics applied to the treatment of osteoporosis, and she has recently been awarded with a grant from the Scottish Chief Scientist Office to perform genetic profiling to predict the response to treatment in patients with severe osteoporosis.
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. See more at www.cost.eu.
